| Withdrawn | A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Blad NCT07342517 | Relmada Therapeutics, Inc. | Phase 3 |
| Not Yet Recruiting | A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder C NCT07464145 | Relmada Therapeutics, Inc. | Phase 3 |
| Withdrawn | A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NM NCT07313891 | Relmada Therapeutics, Inc. | Phase 3 |
| Enrolling By Invitation | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid T NCT07218003 | Rondo Therapeutics | Phase 1 |
| Not Yet Recruiting | JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, NCT06901934 | Zeinab Yahia Zaki | — |
| Recruiting | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors NCT07020117 | Aktis Oncology, Inc. | Phase 1 |
| Not Yet Recruiting | A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. NCT07064863 | Queen's University | Phase 1 / Phase 2 |
| Recruiting | Intervention of Bladder Cancer by CAR-T NCT03185468 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | Bladder EpiCheck European Haematuria Study NCT06818136 | Nucleix Ltd. | — |
| Active Not Recruiting | Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases NCT06870253 | Pangea Laboratory LLC | — |
| Recruiting | Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial C NCT06983210 | Nagoya University | Phase 2 |
| Recruiting | Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer NCT06586255 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Active Not Recruiting | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors NCT06714617 | SystImmune Inc. | Phase 1 |
| Recruiting | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma NCT06823427 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 |
| Recruiting | Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity NCT06806059 | Ludwig-Maximilians - University of Munich | N/A |
| Recruiting | Renal Retention in High Grade Upper Tract Urothelial Cancer NCT05656235 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | A Study of VET3-TGI in Patients With Solid Tumors NCT06444815 | KaliVir Immunotherapeutics | Phase 1 |
| Recruiting | Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy NCT06184516 | University of Florida | Phase 2 |
| Active Not Recruiting | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Blad NCT06331299 | UroGen Pharma Ltd. | Phase 3 |
| Recruiting | Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle NCT05037279 | Verity Pharmaceuticals Inc. | Phase 3 |
| Terminated | Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant NCT05839119 | Brown University | Phase 1 |
| Recruiting | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform NCT05520099 | Elephas | — |
| Withdrawn | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss NCT06090318 | Rain Oncology Inc | Phase 1 / Phase 2 |
| Unknown | Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume NCT05701332 | Assiut University | Phase 4 |
| Recruiting | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer NCT05483868 | Aura Biosciences | Phase 1 |
| Recruiting | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer NCT05312671 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIB NCT05375903 | UroGen Pharma Ltd. | Phase 1 |
| Unknown | Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle I NCT05401279 | RenJi Hospital | Phase 2 |
| Completed | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCH NCT05077709 | IO Biotech | Phase 2 |
| Active Not Recruiting | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder NCT05243550 | UroGen Pharma Ltd. | Phase 3 |
| Active Not Recruiting | Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder C NCT05241340 | The Methodist Hospital Research Institute | Phase 2 |
| Completed | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer NCT05136898 | UroGen Pharma Ltd. | Phase 3 |
| Terminated | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer NCT04688931 | UroGen Pharma Ltd. | Phase 3 |
| Unknown | Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic NCT04770974 | University of Florence | — |
| Active Not Recruiting | Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer NCT04386746 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963 | Ikena Oncology | Phase 1 |
| Completed | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer NCT03558503 | UroGen Pharma Ltd. | Phase 2 |
| Terminated | A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Adv NCT03606174 | Mirati Therapeutics Inc. | Phase 2 |
| Completed | Phase Ib of L-NMMA and Pembrolizumab NCT03236935 | The Methodist Hospital Research Institute | Phase 1 |
| Unknown | Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer NCT04740866 | Cairo University | N/A |
| Unknown | En Bloc Bladder Tumor Resection: Prospective Randomized Study NCT04712201 | Fundacio Puigvert | N/A |
| Active Not Recruiting | Bladder Cancer Adjuvant Radiotherapy Trial NCT02951325 | Tata Memorial Centre | Phase 3 |